CN112156065A - 一种含地夸磷索钠的隐形眼镜及其制备方法 - Google Patents
一种含地夸磷索钠的隐形眼镜及其制备方法 Download PDFInfo
- Publication number
- CN112156065A CN112156065A CN202011059230.7A CN202011059230A CN112156065A CN 112156065 A CN112156065 A CN 112156065A CN 202011059230 A CN202011059230 A CN 202011059230A CN 112156065 A CN112156065 A CN 112156065A
- Authority
- CN
- China
- Prior art keywords
- contact lens
- polymer
- solution
- sodium
- diquafosol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NMLMACJWHPHKGR-NCOIDOBVSA-N P(1),P(4)-bis(uridin-5'-yl) tetraphosphate Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N2C(NC(=O)C=C2)=O)O)O)C=CC(=O)NC1=O NMLMACJWHPHKGR-NCOIDOBVSA-N 0.000 title claims abstract description 27
- 229950003529 diquafosol Drugs 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 32
- 229920000642 polymer Polymers 0.000 claims abstract description 24
- 239000000243 solution Substances 0.000 claims abstract description 19
- 239000000178 monomer Substances 0.000 claims abstract description 10
- 238000010526 radical polymerization reaction Methods 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 3
- 229940079593 drug Drugs 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- 239000003431 cross linking reagent Substances 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 10
- 239000011259 mixed solution Substances 0.000 claims description 10
- 239000011734 sodium Substances 0.000 claims description 10
- 229910052708 sodium Inorganic materials 0.000 claims description 10
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- 125000004386 diacrylate group Chemical group 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 claims description 7
- GJKGAPPUXSSCFI-UHFFFAOYSA-N 2-Hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone Chemical compound CC(C)(O)C(=O)C1=CC=C(OCCO)C=C1 GJKGAPPUXSSCFI-UHFFFAOYSA-N 0.000 claims description 7
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 238000006116 polymerization reaction Methods 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- UWFRVQVNYNPBEF-UHFFFAOYSA-N 1-(2,4-dimethylphenyl)propan-1-one Chemical compound CCC(=O)C1=CC=C(C)C=C1C UWFRVQVNYNPBEF-UHFFFAOYSA-N 0.000 claims description 2
- KMNCBSZOIQAUFX-UHFFFAOYSA-N 2-ethoxy-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(OCC)C(=O)C1=CC=CC=C1 KMNCBSZOIQAUFX-UHFFFAOYSA-N 0.000 claims description 2
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 claims description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 2
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 2
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003889 eye drop Substances 0.000 abstract description 14
- 229940012356 eye drops Drugs 0.000 abstract description 10
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 239000000499 gel Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 6
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 5
- 206010013774 Dry eye Diseases 0.000 description 5
- 238000007872 degassing Methods 0.000 description 5
- 239000000017 hydrogel Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 238000002834 transmittance Methods 0.000 description 5
- 239000000607 artificial tear Substances 0.000 description 4
- 238000012377 drug delivery Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 239000005630 Diquat Substances 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- SYJFEGQWDCRVNX-UHFFFAOYSA-N diquat Chemical compound C1=CC=[N+]2CC[N+]3=CC=CC=C3C2=C1 SYJFEGQWDCRVNX-UHFFFAOYSA-N 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- UDJZTGMLYITLIQ-UHFFFAOYSA-N 1-ethenylpyrrolidine Chemical compound C=CN1CCCC1 UDJZTGMLYITLIQ-UHFFFAOYSA-N 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 231100000478 corneal permeability Toxicity 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000005494 xerophthalmia Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2/00—Processes of polymerisation
- C08F2/46—Polymerisation initiated by wave energy or particle radiation
- C08F2/48—Polymerisation initiated by wave energy or particle radiation by ultraviolet or visible light
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/10—Esters
- C08F220/20—Esters of polyhydric alcohols or phenols, e.g. 2-hydroxyethyl (meth)acrylate or glycerol mono-(meth)acrylate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C7/00—Optical parts
- G02C7/02—Lenses; Lens systems ; Methods of designing lenses
- G02C7/04—Contact lenses for the eyes
- G02C7/049—Contact lenses having special fitting or structural features achieved by special materials or material structures
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2333/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers
- C08J2333/04—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers esters
- C08J2333/14—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers esters of esters containing halogen, nitrogen, sulfur, or oxygen atoms in addition to the carboxy oxygen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种含地夸磷索钠的隐形眼镜及其制备方法，属于药物制剂技术领域。本发明通过将药物溶液与聚合物单体溶液混合后进行自由基聚合反应，再通过紫外照射使聚合物凝胶固化，从而制备的含有地夸磷索钠的隐形眼镜。与市售地夸磷索钠滴眼剂相比，本发明所得制剂可延长药物的释放时间，提高药物的生物利用度，减少给药次数，提高患者的依从性。
Description
技术领域
本发明属于药物制剂技术领域，具体涉及一种含地夸磷索钠的隐形眼镜及其制备方法。
背景技术
干眼综合症是指结膜和角膜没有被健康量或质量的泪液包裹的情况，仅在美国，就有超过五千万人患有干眼症。干眼症包括眼睛瘙痒和灼热、沙粒感、光敏性、视力模糊和炎症，所有这些都会严重影响患者的生活质量。眼睛干涩的患者通过滴眼液、润滑剂、舒适剂或人工泪液，以增加眼泪的黏度，减慢泪液引流并增加眼表水分。
地夸磷索钠滴眼剂是由参天制药获得Inspire制药公司授权后开发，最早于2010年10月在日本获批用于干眼症的治疗，商品名为
规格为3％(5mL)。国内在2017年10月获批进口，商品名为丽爱思。地夸磷索钠是一种P2Y2受体激动剂，其作用于结膜上皮及杯状细胞膜上的P2Y2受体，通过上调细胞内的钙离子浓度，促进水分及黏蛋白的分泌，进而改善干眼病症状。目前，上市的地夸磷索钠制剂仅有滴眼剂，需一天给药六次。
传统滴眼液有许多缺点，如生物利用度低、眼部停留时间短，为了弥补这些问题，就需要增加药物的剂量或者需要频繁局部用药，这导致患者依从性较差。
目前，已经出现了一些新颖的药物递送系统来改善眼用药物的停留时间和角膜渗透性，例如软膏剂、眼用凝胶等，但是它们有其自身的局限性。因此，需要一种新型的药物递送系统，可以增加药物的生物利用度，最小化药物的全身暴露并改善患者依从性以取得更好的临床效果。通过隐形眼镜进行药物递送就是其中一种，与滴眼剂疗法相比，它们具有独特的优势，是用于眼部药物输送的理想载体，这是因为：1)软性隐形眼镜可长时间安全舒适地佩戴；2)与滴眼剂相比，药物在角膜停留时间大大增加，可提高生物利用度(＞50％)；3)易于终止治疗(通过移除隐形眼镜)；4)对于需要屈光校正的患者依从性也较好。
现有的制备载药隐形眼镜的方法有：1)药物浸泡法，此方法最简便易操作，但是存在药物突释和缓释效果差的问题，并且载药量受到比较大的限制，例如药物的分子量、药物在水凝胶中的溶解性等，难以达到长期释放有效药物浓度的效果；2)官能团引入法，具有与水凝胶结合位点的药物可通过此法进行载药，在泪液中，离子通过与药物竞争水凝胶上的结合位点，从而释放药物，但此类方法研究较少；3)载药胶体颗粒引入法，可先将药物负载与纳米粒、脂质体等胶体颗粒中，再将胶体颗粒分散在凝胶聚合液中，形成负载胶体颗粒的水凝胶，但是该方法的缺陷在于胶体颗粒的结构可能影响隐形眼镜的透氧性；4)分子印迹法，该方法是在药物存在的情况下聚合官能团，然后去除药物使得产生空腔，再通过空腔内的官能团与药物发生共价作用，使得药物装载于空腔内，从而改变药物的装载和释放，但是分子印迹中的高度交联会改变隐形眼镜的光学和物理特性。
目前地夸磷酸钠仅有滴眼液产品上市，开发给药次数少或给药剂量小，使用方便的产品，更好的提高地夸磷索钠的疗效具有非常好的市场前景。
发明内容
本发明的目的在于提供一种含地夸磷索钠的隐形眼镜及其制备方法，该制剂与传统的滴眼剂相比，能够增加药物在眼表的停留时间，达到缓释给药，提高生物利用度，解决了传统滴眼剂存在的给药频繁的问题。
为了实现上述发明目的，本发明采用以下技术方案：
一种含地夸磷索钠的隐形眼镜，所述隐形眼镜为固化的聚合物凝胶；
所述聚合物凝胶由聚合物混合液经自由基聚合反应得到，所述聚合物混合液的原料包括：聚合物单体、交联剂、光引发剂和地夸磷索钠。
进一步地，所述聚合物混合液中地夸磷索钠、聚合物单体、交联剂和光引发剂的浓度分别为：3wt％、0.05wt％～0.5wt％、0.003～0.015wt％、0.1～1wt％。
进一步地，所述聚合物单体选自甲基丙烯酸羟乙酯、N-乙烯基吡咯烷酮、甲基丙烯酸中的一种或多种。
进一步地，所述交联剂选自聚乙二醇二丙烯酸酯、乙二醇二甲基丙烯酸酯或乙二醇二缩水甘油醚中的一种或多种。
进一步地，所述光引发剂选自Irgacure 2959、安息香乙醚、硫酸氨或四甲基乙二胺中的一种或多种。
上述含地夸磷索钠的隐形眼镜的制备方法，包括以下步骤：
步骤1，将地夸磷索钠溶于水中，搅拌使其完全溶解，得到药物溶液；
步骤2，将聚合单体、交联剂加至水中混合，向混合溶液中加入药物溶液，配制成含药物的聚合液；
步骤3，向聚合液中加入光引发剂水溶液，搅拌使其溶解，向混合溶液中通入氮气以除去溶液中的氧气；
步骤4，将聚合物混合液倒入模具中，通过紫外照射使凝胶固化，即可得到隐形眼镜。
有益效果：与市售传统滴眼剂相比，本发明的隐形眼镜采用聚合物水凝胶作为药物载体，地夸磷索钠缓释效果显著，并且不存在明显的突释现象。聚合物凝胶固化后得到的隐形眼镜，镜片的关键特性如溶胀率，透射率等均较好，符合镜片要求。
附图说明
图1为实施例1-5的隐形眼镜的体外释放度曲线。
具体实施方式
以下将通过具体实施例进一步阐述本发明，应当理解，本发明的实施例仅用于理解本发明，而非对本发明的限制。未特别说明，本发明的术语具有本领域的常规含义，所有试剂均为市售购得后直接使用。
实施例1
精密称定甲基丙烯酸羟乙酯10mg、N-乙烯基吡咯烷酮4mg、聚乙二醇二丙烯酸酯0.3mg，加水9mL，反应形成自由基聚合溶液，然后添加300mg/mL地夸磷索钠水溶液1mL，搅拌均匀后，添加12.5mg的Irgacure 2959，搅拌均匀。将反应混合物用氮气脱气15min后，将混合物倒入模具，在325nm处进行紫外照射，照射时间为30min，使凝胶固化，即得。
实施例2
精密称定甲基丙烯酸羟乙酯10mg，N-乙烯基吡咯烷5mg，聚乙二醇二丙烯酸酯0.3mg，加水9mL，反应形成自由基聚合溶液，然后添加300mg/mL地夸磷索钠水溶液1mL，搅拌均匀后，添加12.5mg的Irgacure 2959，搅拌均匀。将反应混合物用氮气脱气15min后，将混合物倒入模具，在325nm处进行紫外照射，照射时间为30min，使凝胶固化，即得。
实施例3
精密称定甲基丙烯酸羟乙酯10mg，N-乙烯基吡咯烷4mg，聚乙二醇二丙烯酸酯0.8mg，加水9mL，反应形成自由基聚合溶液，然后添添加300mg/mL地夸磷索钠水溶液1mL，搅拌均匀后，添加12.5mg的Irgacure 2959，搅拌均匀。将反应混合物用氮气脱气15min后，将混合物倒入模具，在325nm处进行紫外照射，照射时间为30min，使凝胶固化，即得。
实施例4
精密称定甲基丙烯酸羟乙酯10mg，N-乙烯基吡咯烷酮5mg，聚乙二醇二丙烯酸酯0.8mg，加水9mL，反应形成自由基聚合溶液，然后添加300mg/mL地夸磷索钠水溶液1mL，搅拌均匀后，添加12.5mg的Irgacure 2959，搅拌均匀。将反应混合物用氮气脱气15min后，将混合物倒入模具，在325nm处进行紫外照射，照射时间为30min，使凝胶固化，即得。
实施例5
精密称定甲基丙烯酸羟乙酯10mg，N-乙烯基吡咯烷酮6mg，聚乙二醇二丙烯酸酯1.5mg，加水9mL，反应形成自由基聚合溶液，然后添加300mg/mL地夸磷索钠水溶液1mL，搅拌均匀后，添加12.5mg的Irgacure 2959，搅拌均匀。将反应混合物用氮气脱气15min后，将混合物倒入模具，在325nm处进行紫外照射，照射时间为30min，使凝胶固化，即得。
下面对实施例1-5制得的隐形眼镜进行溶胀率、透射率和体外释放度的检测。
1.溶胀率测定
将称重的干凝胶(Wdry)浸入35℃的磷酸盐缓冲溶液(PBS，pH＝7.4)中，定期从水中移出，表面轻轻干燥，然后称重(Wwet)。吸水能力使用以下公式计算：
结果如下表：
| 处方名称 | 含水量(％) |
| 实施例1 | 51.40 |
| 实施例2 | 52.80 |
| 实施例3 | 59.68 |
| 实施例4 | 60.79 |
| 实施例5 | 67.11 |
由上表可知，随着亲水性共聚单体N-乙烯基吡咯烷酮以及交联剂聚乙二醇二丙烯酸酯含量增加，所制得隐形眼镜的溶胀率增加，因为亲水性单体可增加亲水基团的数量，交联剂增加会导致交联密度增加，水分子在“刚性结构”中的迁移率降低，故所形成的凝胶中的水都以紧密的方式结合在凝胶中。
2.透射率测定
将实施例1-5所得隐形眼镜置于磷酸盐缓冲溶液(PBS，pH＝7.4)中浸泡过夜。使用紫外可见分光光度计在200至900nm的范围内测量了隐形眼镜的光学特性。结果如下表：
| 处方名称 | 透射率(％) |
| 实施例1 | 96.5 |
| 实施例2 | 96.1 |
| 实施例3 | 97.1 |
| 实施例4 | 97.4 |
| 实施例5 | 98.7 |
由上表可知，亲水性共聚单体N-乙烯基吡咯烷酮对透射率无影响，随着交联剂聚乙二醇二丙烯酸酯含量增加，所制得隐形眼镜的透射率增加，说明交联剂增加，隐形眼镜的透明度越好。
3.体外释放度考察
将实施例1-5所得隐形眼镜放入装有100mL人工泪液的烧杯中，置于气浴恒温振荡器中，温度为(37±0.5)℃，转速为100rpm/min，分别于5min、10min、15min、30min、1h、2h、4h、6h、8h及12h取样5mL，过0.45μm水系滤器，取续滤液用人工泪液稀释至合适范围浓度，取市售地夸磷索钠滴眼剂适量，装于透析袋中，也置于同一条件下，操作同上。以人工泪液为空白溶液，参照2020版《中华人民共和国药典》四部中的紫外—可见分光光度法(通则0401)，分别测定吸光度，以外标法计算浓度，并计算累计释放度。
结果如图1所示。由图1可知，市售滴眼剂在不到10h就已经基本释放完毕，实施例1～5的释放均较慢，其中，实施例1～4的释放速率差异不大，均在24h时释放完毕，实施例5缓释效果最佳，24h后仍未完全释放，相较于市售滴眼剂，释药时间大大延长，表明，本发明所制得含地夸磷索钠的隐形眼镜能延长药物的释放时间，较好的解决给药频繁的问题。
Claims (6)
1.一种含地夸磷索钠的隐形眼镜，其特征在于：所述隐形眼镜为固化的聚合物凝胶；
所述聚合物凝胶由聚合物混合液经自由基聚合反应得到，所述聚合物混合液为地夸磷索钠、聚合物单体、交联剂和光引发剂的混合水溶液。
2.根据权利要求1所述的隐形眼镜，其特征在于：所述聚合物混合液中地夸磷索钠、聚合物单体、交联剂和光引发剂的浓度分别为：3wt%、0.05wt%~0.5wt%、0.003~0.015wt%、0.1~1wt%。
3.根据权利要求1或2所述的隐形眼镜，其特征在于：所述聚合物单体选自甲基丙烯酸羟乙酯、N-乙烯基吡咯烷酮、甲基丙烯酸中的一种或多种。
4.根据权利要求1或2所述的隐形眼镜，其特征在于：所述交联剂选自聚乙二醇二丙烯酸酯、乙二醇二甲基丙烯酸酯或乙二醇二缩水甘油醚中的一种或多种。
5.根据权利要求1或2所述的隐形眼镜，其特征在于：所述光引发剂选自Irgacure2959、安息香乙醚、硫酸氨或四甲基乙二胺中的一种或多种。
6.权利要求1所述的含地夸磷索钠的隐形眼镜的制备方法，其特征在于：包括以下步骤：
步骤1，将地夸磷索钠溶于水中，搅拌使其完全溶解，得到药物溶液；
步骤2，将聚合物单体、交联剂加至水中混合，向混合溶液中加入药物溶液，配制成含药物的聚合液；
步骤3，向聚合液中加入光引发剂，搅拌使其溶解，向混合溶液中通入氮气以除去溶液中的氧气；
步骤4，将聚合物混合液倒入模具中，通过紫外照射使凝胶固化，即可得到隐形眼镜。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011059230.7A CN112156065A (zh) | 2020-09-30 | 2020-09-30 | 一种含地夸磷索钠的隐形眼镜及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011059230.7A CN112156065A (zh) | 2020-09-30 | 2020-09-30 | 一种含地夸磷索钠的隐形眼镜及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112156065A true CN112156065A (zh) | 2021-01-01 |
Family
ID=73861652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011059230.7A Pending CN112156065A (zh) | 2020-09-30 | 2020-09-30 | 一种含地夸磷索钠的隐形眼镜及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112156065A (zh) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050074497A1 (en) * | 2003-04-09 | 2005-04-07 | Schultz Clyde L. | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
| US20050255144A1 (en) * | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
| CN102344523A (zh) * | 2011-07-05 | 2012-02-08 | 金陵科技学院 | 一种载药的角膜接触镜用水凝胶的制备方法 |
| CN109239944A (zh) * | 2017-07-11 | 2019-01-18 | 鸿富锦精密工业（深圳）有限公司 | 能够检测眼泪中葡萄糖含量的隐形眼镜及其制备方法 |
| CN109260146A (zh) * | 2018-10-12 | 2019-01-25 | 广州大光制药有限公司 | 地夸磷索钠眼用即用型凝胶滴眼液及制备方法 |
| CN111419851A (zh) * | 2020-04-15 | 2020-07-17 | 天津医科大学 | 缓控释给药的布林佐胺印迹水凝胶隐形眼镜的制备方法 |
| CN111499808A (zh) * | 2020-04-14 | 2020-08-07 | 天津医科大学 | 载药型分子印迹软性隐形眼镜和制备方法 |
-
2020
- 2020-09-30 CN CN202011059230.7A patent/CN112156065A/zh active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050074497A1 (en) * | 2003-04-09 | 2005-04-07 | Schultz Clyde L. | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
| US20050255144A1 (en) * | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
| CN102344523A (zh) * | 2011-07-05 | 2012-02-08 | 金陵科技学院 | 一种载药的角膜接触镜用水凝胶的制备方法 |
| CN109239944A (zh) * | 2017-07-11 | 2019-01-18 | 鸿富锦精密工业（深圳）有限公司 | 能够检测眼泪中葡萄糖含量的隐形眼镜及其制备方法 |
| CN109260146A (zh) * | 2018-10-12 | 2019-01-25 | 广州大光制药有限公司 | 地夸磷索钠眼用即用型凝胶滴眼液及制备方法 |
| CN111499808A (zh) * | 2020-04-14 | 2020-08-07 | 天津医科大学 | 载药型分子印迹软性隐形眼镜和制备方法 |
| CN111419851A (zh) * | 2020-04-15 | 2020-07-17 | 天津医科大学 | 缓控释给药的布林佐胺印迹水凝胶隐形眼镜的制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| CARMEN DOMINGUEZ-GODINEZ等: "Diquafosol Delivery from Silicone Hydrogel Contact Lenses: Improved Effect on Tear Secretion", 《JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4931279A (en) | Sustained release formulation containing an ion-exchange resin | |
| CN102344523B (zh) | 一种载药的角膜接触镜用水凝胶的制备方法 | |
| Kong et al. | Chitosan temperature‑sensitive gel loaded with drug microspheres has excellent effectiveness, biocompatibility and safety as an ophthalmic drug delivery system | |
| KR101877031B1 (ko) | 약물이 담지된 콘택트렌즈 | |
| CN103800949B (zh) | 具有仿生特性的角膜接触镜药物载体及其制备方法 | |
| CN114469851A (zh) | 一种地夸磷索钠眼用温度敏感型凝胶剂及其制备方法 | |
| US20220079877A1 (en) | Devices and methods for reducing cystine crystals in vivo | |
| Thacker et al. | Biomaterials for dry eye disease treatment: Current overview and future perspectives | |
| CN111499808B (zh) | 载药型分子印迹软性隐形眼镜和制备方法 | |
| CN112156065A (zh) | 一种含地夸磷索钠的隐形眼镜及其制备方法 | |
| CN112972371A (zh) | 一种缓释型立他司特滴眼液及其制备方法与应用 | |
| Wei et al. | RETRACTED ARTICLE: Hyaluronic Acid-Pluronic® F127-Laden Soft Contact Lenses for Corneal Epithelial Healing: In Vitro and In Vivo Studies | |
| CN111419851A (zh) | 缓控释给药的布林佐胺印迹水凝胶隐形眼镜的制备方法 | |
| CN104368006B (zh) | 含聚合物胶束的水凝胶眼药载体及其制备方法 | |
| CN114545658B (zh) | 一种药物缓释型互穿网络水凝胶隐形眼镜的制备方法 | |
| CN112415773B (zh) | 一种促进角膜上皮损伤修复的载药接触镜及其制备方法 | |
| CN113559059B (zh) | 一种阳离子纳米混悬液及其制备方法和应用 | |
| JP2005507866A (ja) | 管理治療のための薬物放出システム | |
| Yu Malyutina et al. | Investigation of Releasing Therapeutic Solutions from Soft Contact Lens Surfaces Constructed by Nanoparticles | |
| CN113786380A (zh) | 一种硝酸毛果芸香碱眼用凝胶及其制备方法 | |
| Hu et al. | Development and evaluation of puerarin loaded-albumin nanoparticles thermoresponsive in situ gel for ophthalmic delivery | |
| CN102198087B (zh) | 一种不含防腐剂的眼用原位胶凝剂及其制备方法 | |
| CN103142463B (zh) | 眼用药物组合物,其制备方法及应用 | |
| US20220313615A1 (en) | Nanoparticle Capable of Loading and Releasing Active Constituents, Production Method and Application Thereof | |
| Das et al. | Contact lenses: A development towards ocular drug delivery system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210101 |
|
| RJ01 | Rejection of invention patent application after publication |